According to the American Lyme Disease Foundation, Lyme disease is caused by the bite of a deer tick, which transmits the infection of Borrelia Burgdorfer, a type of spirochete bacterium, through its bite. The bacterium travels through the bloodstream and settles in various body tissues. The clinical manifestations of Lyme disease are a circular skin rash (erythema migrans) at the site of the bite, fever, headaches, muscle and joint pain, and lethargy. As per the latest research findings of the Bay Area Lyme Foundation, in the United States, every year, approximately 329,000 cases of Lyme disease are reported. It is thriving in the northern Midwest and California of the United States, as well as in Western Europe. Lyme disease is caused by four bacterial species, such as Borrelia burgdorferi, Borrelia afzelii, Borrelia mayonii, and Borrelia garinii. The key drivers responsible for the growth of Lyme disease diagnostics are the rampant spread of the disease and rising public health awareness, resulting in early diagnosis and treatment.
According to the research findings of the World Health Organization (WHO), Lyme disease usually occurs in the summer. They are prevalent in the forested areas of the U.S., Asia, and Europe. The disease is fatal as it affects the central nervous system, and arthritis usually develops within two years of infection. Currently, there is no prophylaxis available for Lyme disease; avoiding deer tick-infested areas, and exposure is the best precaution. The diagnosis of Lyme disease is very sensitive and critical; approximately 55% of the current diagnostic testing solutions are inaccurate, and more than 20% of the patients receiving treatment in the early stages of Lyme disease continue to have symptoms. Doxycycline, cefuroxime axetil, and amoxicillin are currently prescribed for the treatment of Lyme disease. In July 2017, the USFDA gave fast-track designation to VLA15, a Lyme disease vaccine candidate developed by Valneva SE.
The Lyme disease diagnostic market is divided into the following categories:
- Western Blot
- Urine antigen tests
- Lymphocytic Transformation Examinations
- Immunofluorescent Staining
- Nucleic acid tests
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Key players identified for the Lyme disease diagnostic market include:
Abbott Laboratories, Inc., Alere, Inc., Bio-Rad Laboratories, Canon Life Sciences, Global Lyme Diagnostics, Graphene Frontiers, Oxford Immunotec, and Trinity Biotech
This report offers the following:
- The market assessment is performed by considering the market size for the base year of 2017 and the compound annual growth rate for the forecast period of 2018 to 2026.
- The market size and forecast are presented for the period from 2016 to 2026.
- The competitive landscape gives a brief insight into the existing competitive environment among the key players actively engaged in the diagnosis of Lyme disease.
- Attractive investment propositions by geography are provided by taking vital facts such as market size and CAGR of different diagnostic technologies, as well as the prevalence of Lyme disease in the geographical regions, into account.
- In the company profiles segment, we provide insights into the product portfolios, financial performance, and key developments of the major players offering diagnostic solutions for the detection and confirmation of Lyme disease.